Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?

Company Overview - Jazz Pharmaceuticals (JAZZ) shares have increased by approximately 7.9% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Jazz Pharmaceuticals have trended downward, with a consensus estimate shift of -213.47% over the past month [2] - The overall trend indicates a negative outlook for the stock's performance [4] VGM Scores - Jazz Pharmaceuticals has a Growth Score of B, but a low Momentum Score of F, while maintaining a Value Score of B, placing it in the top 40% for value investment strategy [3] - The aggregate VGM Score for the stock is B, which is significant for investors not focused on a single strategy [3] Industry Performance - Jazz operates within the Zacks Medical - Biomedical and Genetics industry, where another player, Alkermes (ALKS), has seen a 3.8% gain over the past month [5] - Alkermes reported revenues of $306.51 million for the last quarter, reflecting a year-over-year decline of -12.5% [5] - Alkermes is expected to post earnings of $0.43 per share for the current quarter, indicating a year-over-year change of -40.3% [6]